Several in vitro models have been developed to mimic chronic lymphocytic leukemia (CLL) proliferation in immune niches; however, they typically do not induce robust proliferation. We prepared a novel model based on mimicking T-cell signals in vitro and in patient-derived xenografts (PDXs). Six supportive cell lines were prepared by engineering HS5 stromal cells with stable expression of human CD40L, IL4, IL21, and their combinations. Co-culture with HS5 expressing CD40L and IL4 in combination led to mild CLL cell proliferation (median 7% at day 7), while the HS5 expressing CD40L, IL4, and IL21 led to unprecedented proliferation rate (median 44%). The co-cultures mimicked the gene expression fingerprint of lymph node CLL cells (MYC, NFκB, and E2F signatures) and revealed novel vulnerabilities in CLL-T-cell-induced proliferation. Drug testing in co-cultures revealed for the first time that pan-RAF inhibitors fully block CLL proliferation. The co-culture model can be downscaled to five microliter volume for large drug screening purposes or upscaled to CLL PDXs by HS5-CD40L-IL4 ± IL21 co-transplantation. Co-transplanting NSG mice with purified CLL cells and HS5-CD40L-IL4 or HS5-CD40L-IL4-IL21 cells on collagen-based scaffold led to 47% or 82% engraftment efficacy, respectively, with ~20% of PDXs being clonally related to CLL, potentially overcoming the need to co-transplant autologous T-cells in PDXs.

Central European Institute of Technology Brno University of Technology Brno Czech Republic

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Histology and Embryology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Pathology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Science Masaryk University Brno Czech Republic

See more in PubMed

Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94:193–205. 10.1111/ejh.12427 PubMed DOI

Herndon TM, Chen S-S, Saba NS, Valdez J, Emson C, Gatmaitan M, et al. Direct in vivo Evidence for Increased Proliferation of CLL Cells in Lymph Nodes Compared to Bone Marrow and Peripheral Blood. Leukemia. 2017;31:1340–7. 10.1038/leu.2017.11 PubMed DOI PMC

Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–74. 10.1182/blood-2010-05-284984 PubMed DOI PMC

Hoferkova E, Kadakova S, Mraz M. In Vitro and In Vivo Models of CLL–T Cell Interactions: Implications for Drug Testing. Cancers. 2022;14:3087. 10.3390/cancers14133087 PubMed DOI PMC

Schleiss C, Ilias W, Tahar O, Güler Y, Miguet L, Mayeur-Rousse C, et al. BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Sci Rep. 2019;9:701. 10.1038/s41598-018-36853-8 PubMed DOI PMC

Ahearne MJ, Willimott S, Piñon L, Kennedy DB, Miall F, Dyer MJS, et al. Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. Br J Haematol. 2013;162:360–70. 10.1111/bjh.12401 PubMed DOI

Os A, Bürgler S, Ribes AP, Funderud A, Wang D, Thompson KM, et al. Chronic Lymphocytic Leukemia Cells Are Activated and Proliferate in Response to Specific T Helper Cells. Cell Rep. 2013;4:566–77. 10.1016/j.celrep.2013.07.011 PubMed DOI

Pascutti MF, Jak M, Tromp JM, Derks IAM, Remmerswaal EBM, Thijssen R, et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood. 2013;122:3010–9. 10.1182/blood-2012-11-467670 PubMed DOI

Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, et al. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol. 2012;158:589–99. 10.1111/j.1365-2141.2012.09191.x PubMed DOI

Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PEM, Simone R, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011;117:5463–72. 10.1182/blood-2010-12-324210 PubMed DOI PMC

Patten PEM, Ferrer G, Chen S-S, Kolitz JE, Rai KR, Allen SL et al. A detailed analysis of parameters supporting the engraftment and growth of chronic lymphocytic leukemia cells in immune-deficient mice. Front Immunol. 2021;12:627020. PubMed PMC

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42. 10.1056/NEJMoa1215637 PubMed DOI PMC

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007. 10.1056/NEJMoa1315226 PubMed DOI PMC

Ponader S, Chen S-S, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9. 10.1182/blood-2011-10-386417 PubMed DOI PMC

Seda V, Vojackova E, Ondrisova L, Kostalova L, Sharma S, Loja T, et al. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. Blood. 2021;138:758–72. 10.1182/blood.2020008101 PubMed DOI PMC

Luo W, Weisel F, Shlomchik MJ. B Cell Receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells. Immunity. 2018;48:313–.e5. 10.1016/j.immuni.2018.01.008 PubMed DOI PMC

Tretter T, Schuler M, Schneller F, Brass U, Esswein M, Aman MJ, et al. Direct Cellular Interaction with Activated CD4+T Cells Overcomes Hyporesponsiveness of B-Cell Chronic Lymphocytic Leukemiain Vitro. Cell Immunol. 1998;189:41–50. 10.1006/cimm.1998.1360 PubMed DOI

Haselager MV, Kater AP, Eldering E. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Front Oncol. 2020;10:592205. PubMed PMC

Haselager MV, Driel BF van, Perelaer E, Rooij D de, Lashgari D, Loos R, et al. In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival. Hemasphere. 2023;7:e938. PubMed PMC

Sbrana FV, Pinos R, Barbaglio F, Ribezzi D, Scagnoli F, Scarfò L, et al. 3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells. Front Immunol. 2021;12:639572. 10.3389/fimmu.2021.639572 PubMed DOI PMC

Herbst SA, Kim V, Roider T, Schitter EC, Bruch P-M, Liebers N, et al. Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies. Blood Adv. 2023;7:5925–36. PubMed PMC

Hermansen JU, Yin Y, Urban A, Myklebust CV, Karlsen L, Melvold K, et al. A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine. Cell Death Discov. 2023;9:1–10. 10.1038/s41420-023-01426-w PubMed DOI PMC

Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011;155:53–64. 10.1111/j.1365-2141.2011.08794.x PubMed DOI PMC

Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128:1609–13. 10.1182/blood-2016-04-709519 PubMed DOI PMC

Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114:4441–50. 10.1182/blood-2009-07-233718 PubMed DOI PMC

Willimott S, Baou M, Naresh K, Wagner SD. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol. 2007;138:721–32. 10.1111/j.1365-2141.2007.06717.x PubMed DOI

Prosecká E, Rampichová M, Vojtová L, Tvrdík D, Melčáková Š, Juhasová J, et al. Optimized conditions for mesenchymal stem cells to differentiate into osteoblasts on a collagen/hydroxyapatite matrix. J Biomed Mater Res. 2011;99A:307–15.10.1002/jbm.a.33189 PubMed DOI

Bartholdy BA, Wang X, Yan X-J, Pascual M, Fan M, Barrientos J, et al. CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. Blood Adv. 2020;4:893–905. 10.1182/bloodadvances.2019000817 PubMed DOI PMC

Calissano C, Damle RN, Marsilio S, Yan X-J, Yancopoulos S, Hayes G, et al. Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells. Mol Med. 2011;17:1374–82. 10.2119/molmed.2011.00360 PubMed DOI PMC

Cuthill KM, Zhang Y, Pepper A, Boelen L, Coulter E, Asquith B, et al. Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL. Leukemia. 2022;36:2233–41. 10.1038/s41375-022-01656-4 PubMed DOI PMC

Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, et al. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018;32:2028–31. 10.1038/s41375-018-0211-0 PubMed DOI

Sharma S, Pavlasova GM, Seda V, Cerna KA, Vojackova E, Filip D, et al. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021;137:2481–94. 10.1182/blood.2020005627 PubMed DOI PMC

Sandova V, Pavlasova GM, Seda V, Cerna KA, Sharma S, Palusova V et al. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib. Haematology. 2021;106:2995–9. PubMed PMC

Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523–30. 10.1093/bioinformatics/btt703 PubMed DOI PMC

Sun C, Chen Y-C, Martinez AZ, Baptista MJ, Pittaluga S, Liu D, et al. The Immune Microenvironment Shapes Transcriptional and Genetic Heterogeneity in Chronic Lymphocytic Leukemia. Blood Adv. 2023;7:145–58. PubMed PMC

Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995;85:997–1005. 10.1182/blood.V85.4.997.bloodjournal854997 PubMed DOI

Néron S, Nadeau PJ, Darveau A, Leblanc J-F. Tuning of CD40–CD154 Interactions in Human B-Lymphocyte Activation: A Broad Array of In Vitro Models for a Complex In Vivo Situation. Arch Immunol Ther Exp. 2011;59:25–40.10.1007/s00005-010-0108-8 PubMed DOI

Dühren-von Minden M, Übelhart R, Schneider D, Wossning T, Bach MP, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489:309–12. 10.1038/nature11309 PubMed DOI

Slinger E, Thijssen R, Kater AP, Eldering E. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017;31:2601–7. 10.1038/leu.2017.129 PubMed DOI

Barrio L, Román-García S, Díaz-Mora E, Risco A, Jiménez-Saiz R, Carrasco YR et al. B Cell Development and T-Dependent Antibody Response Are Regulated by p38γ and p38δ. Front Cell Dev Biol. 2020;8:189. PubMed PMC

Pesu M, Aittomäki S, Takaluoma K, Lagerstedt A, Silvennoinen O. p38 Mitogen-activated Protein Kinase Regulates Interleukin-4-induced Gene Expression by Stimulating STAT6-mediated Transcription. J Biol Chem. 2002;277:38254–61. 10.1074/jbc.M201427200 PubMed DOI

Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, et al. IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31:1605–14. 10.1097/PAS.0b013e31804bdaf8 PubMed DOI

Wu X, Fajardo-Despaigne JE, Zhang C, Neppalli V, Banerji V, Johnston JB, et al. Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia. Front Oncol. 2021;11:674492. 10.3389/fonc.2021.674492 PubMed DOI PMC

Purroy N, Abrisqueta P, Carabia J, Carpio C, Palacio C, Bosch F, et al. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2014;6:7632–43.10.18632/oncotarget.2939 PubMed DOI PMC

de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood. 2006;107:3708–15. 10.1182/blood-2005-09-3535 PubMed DOI

Gowda A, Roda J, Hussain S-RA, Ramanunni A, Joshi T, Schmidt S, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008;111:4723–30. 10.1182/blood-2007-07-099531 PubMed DOI PMC

Vené R, Delfino L, Castellani P, Balza E, Bertolotti M, Sitia R, et al. Redox remodeling allows and controls B-cell activation and differentiation. Antioxid Redox Signal. 2010;13:1145–55. 10.1089/ars.2009.3078 PubMed DOI

Patten PEM, Buggins AGS, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood. 2008;111:5173–81. 10.1182/blood-2007-08-108605 PubMed DOI

Ferrer G, Bosch R, Hodgson K, Tejero R, Roué G, Colomer D, et al. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. Br J Haematol. 2014;164:570–8. 10.1111/bjh.12645 PubMed DOI

Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood. 2005;106:1012–20. 10.1182/blood-2004-03-0889 PubMed DOI PMC

Néron S, Roy A, Dumont N. Large-Scale In Vitro Expansion of Polyclonal Human Switched-Memory B Lymphocytes. PLOS One. 2012;7:e51946. 10.1371/journal.pone.0051946 PubMed DOI PMC

Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018;24:868–80. 10.1038/s41591-018-0028-4 PubMed DOI PMC

Burack WR, Spence JM, Spence JP, Spence SA, Rock PJ, Shenoy GN, et al. Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment. Blood Adv. 2017;1:1263–73. 10.1182/bloodadvances.2017005892 PubMed DOI PMC

Epron G, Ame-Thomas P, Le Priol J, Pangault C, Dulong J, Lamy T, et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia. 2012;26:139–48. 10.1038/leu.2011.179 PubMed DOI

Planken EV, Dijkstra NH, Willemze R, Kluin-Nelemans JC. Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the ‘CD40 system’. Leukemia. 1996;10:488–93. PubMed

Kastenschmidt JM, Schroers-Martin JG, Sworder BJ, Sureshchandra S, Khodadoust MS, Liu CL, et al. A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment. Cell Stem Cell. 2024;31:410–20.e4. 10.1016/j.stem.2024.01.012 PubMed DOI PMC

von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9:212–24. 10.1016/S2213-8587(21)00019-X PubMed DOI

Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, et al. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. J Allergy Clin Immunol Pr. 2020;8:527–39.e9.10.1016/j.jaip.2019.07.016 DOI

Fadul CE, Mao-Draayer Y, Ryan KA, Noelle RJ, Wishart HA, Channon JY, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1096. 10.1212/NXI.0000000000001096 PubMed DOI PMC

Mittal AK, Chaturvedi NK, Rai KJ, Gilling-Cutucache CE, Nordgren TM, Moragues M, et al. Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease. Mol Med. 2014;20:290–301. 10.2119/molmed.2012.00303 PubMed DOI PMC

Fecteau J-F, Bharati IS, O’Hayre M, Handel TM, Kipps TJ, Messmer D. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012;18:19–28. 10.2119/molmed.2011.00164 PubMed DOI PMC

Scheffler L, Feicht S, Babushku T, Kuhn LB, Ehrenberg S, Frankenberger S, et al. ERK phosphorylation is RAF independent in naïve and activated B cells but RAF dependent in plasma cell differentiation. Sci Signal. 2021;14:eabc1648. 10.1126/scisignal.abc1648 PubMed DOI

Murali I, Kasar S, Naeem A, Tyekucheva S, Khalsa JK, Thrash EM, et al. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 2021;138:44–56. 10.1182/blood.2020006765 PubMed DOI PMC

Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, et al. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica. 2019;104:576–86. 10.3324/haematol.2018.196931 PubMed DOI PMC

Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen CD, et al. Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. Blood Advances. 2024;May 7. 10.1182/bloodadvances.2024012906 PubMed PMC

Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9:727. 10.1038/s41467-018-03170-7 PubMed DOI PMC

Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D’Rozario J, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. JCO. 2020;38:4042–54.10.1200/JCO.20.00948 PubMed DOI PMC

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, et al. Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches. Blood. 2016;128:2949–59. 10.1182/blood-2016-05-719021 PubMed DOI

Herudkova Z, Culen M, Folta A, Jeziskova I, Cerna J, Loja T, et al. Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. Br J Haematol. 2020;190:562–72. 10.1111/bjh.16341 PubMed DOI

Teramoto N, Gogolák P, Nagy N, Maeda A, Kvarnung K, Björkholm T, et al. Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. J Hum Virol. 2000;3:125–36. PubMed

Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter’s transformation. Am J Hematol. 1999;60:99–104. 10.1002/(SICI)1096-8652(199902)60:2<99::AID-AJH3>3.0.CO;2-T PubMed DOI

Hussaini MO, Rehman A, Chavez JC, Pinilla-Ibarz J, Horna P. EBV-positive Richter’s syndrome with laboratory features of Burkitt’s lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58:1753–6. 10.1080/10428194.2016.1256482 PubMed DOI

Liu Y, Ho C, Roshal M, Baik J, Arcila M, Zhang Y, et al. Transformation of monoclonal B lymphocytosis to Epstein-Barr virus-positive large B-cell lymphoma with intermediate features between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. AJSP Rev Rep. 2019;24:207–11. PubMed PMC

Hussain T, Mulherkar R. Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells to Study Carcinogen Sensitivity and DNA Repair. Int J Mol Cell Med. 2012;1:75–87. PubMed PMC

Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps Involved in Immortalization and Tumorigenesis in Human B-Lymphoblastoid Cell Lines Transformed by Epstein-Barr Virus. Cancer Res. 2004;64:3361–4. 10.1158/0008-5472.CAN-04-0079 PubMed DOI

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia